Real Power Capital
VC Fund
Xuhui, China
Real Power Capital is a VC fund in Xuhui focused on Medical and Biotechnology. Real Power Capital Co., Ltd. is an investment firm specializing in environmental protection, modern information technology, biotechnology, high-end manufacturing equipment, new energy, new material, new energy vehicles, consumer product, healthcare, and services sectors.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Real Power Capital invests in
Stages Real Power Capital invests in
Countries Real Power Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Medical 6 (29%)
- Biotechnology 5 (24%)
- Software 3 (14%)
- Biopharma 3 (14%)
- Health Care 3 (14%)
Stage
- Series B 4 (19%)
- Series C 4 (19%)
- Seed 3 (14%)
- Series A 3 (14%)
- Angel 2 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Shen Furong
Vice President
|
Vice President | Total investments: 0 | Find email | |
|
Sun Sheng
President and Vice Chairman
|
President and Vice Chairman | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Ruanxin Biotechnology
|
Ruanxin Biotechnology focuses on the research and development of injectable cartilage technology. | $14.7M / Seed / Apr 21, 2026 | |
Postek Electronics Co.
|
Postek Electronics Co. is a printing machine manufacturing company that offers the OX series, TX series, GX series, and MX series. | $14.5M / Series C / Mar 18, 2026 | |
Power Site
|
Power Site is a modern technology enterprise that supplies X-ray imaging core components. It mainly provides high-voltage generators (HVG), combined X-ray sources, power distribution units (PDU), and other core components overall solutions for X-ray imaging systems. The products are mainly used in high-end X-ray imaging systems such as CT, DR,mammography, C-arm, CBCT, security inspection, industrial inspection, etc. The company has an advanced and efficient manufacturing platform with an annual production capacity of 50,000 units. | $14.5M / Series C / Mar 18, 2026 | |
|
Hexagonal Diamond Technology
|
Hexagonal Diamond Technology is a new materials technology developer . | Seed / Feb 05, 2026 | |
Hertz Life Science Technology
|
Hertz Life Science Technology uses virus-like particle VLPs technology to develop animal and human vaccines.The company has several underlying core patented technologies and has established a stable and efficient research and development platform based on the Jiyin Biomedical Transformation (Greater Bay Area) base, and actively promotes theresearch and development of vaccines.At present, the company has carried out extensive and in-depth cooperation with large enterprises such as Qingdao Yibang and Wen's Group, and its R&D strength has been highly recognized by peers and upstream and downstream enterprises. | Series A / Jan 28, 2026 | |
Aipuqiang
|
Shanghai Aipuqiang Particle Equipment is committed to providing customers with independently developed advanced proton therapy systems, based on independent innovation and with the mission of creating domestically produced high-end particle therapy technology to benefit cancer patients and contribute to the Healthy China strategy. | $142.7M / Series B / Dec 27, 2025 | |
Tongjia Hongrui Technology
|
Tongjia Hongrui Technology specializes in providing dry vacuum pump equipment and system technology services to the semiconductor sector. | $68.4M / Series C / Apr 07, 2025 | |
Meyer FSMP Hong Kong
|
Meyer FSMP Hong Kong leads the research and development and practical exploration of the oncology special medical food industry.With the support of Hong Kong Meiya Pharmaceutical Factory with nearly 50 years of pharmaceutical history, and with the cooperation of the Chinese mainland oncology product promotion team with 30 years of successfulexperience, Meyer FSMP has entered the special medical food industry across the board, leading the development of domestic nutrition therapy, and is committed to becoming a practitioner of the first-line treatment of tumor nutrition. | $1.4M / Private Equity / Mar 07, 2025 | |
Yantai Lannacheng Biotechnology
|
Yantai Lannacheng Biotechnology is a biotech business that focuses on the building class I diagnosis and therapy integrated novel tumor nuclear medication research and development platform.and therapy integrated novel tumor nuclear medication research and development platform. | $20.6M / Series B / Feb 14, 2025 | |
Ankenmai Biotech
|
Ankenmai Biotech conducts R&D and manufactures consumables for the biopharmaceutical industry. Its primary focus is on the research and production of consumables for the biopharmaceutical industry. | Seed / Jan 25, 2024 | |
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Real Power Capital invest in?
Real Power Capital invests primarily in Medical, Biotechnology and Software startups, most often at Series B and Series C stage. Most of the 21 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Real Power Capital?
Public channels for Real Power Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Real Power Capital?
The team at Real Power Capital includes Shen Furong (Vice President) and Sun Sheng (President and Vice Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
